288 filings
Page 6 of 15
424B3
s0d4c llskr
12 Sep 19
Prospectus supplement
5:06pm
424B3
ogwq847w
12 Sep 19
Prospectus supplement
5:02pm
8-K
xv9c1td3b79ui0w7c0
10 Sep 19
Intra-Cellular Therapies Provides Lumateperone Regulatory Update
7:39am
UPLOAD
1kck3
10 Sep 19
Letter from SEC
12:00am
CORRESP
zkfh6zaq4x3sgztpyct
10 Sep 19
Correspondence with SEC
12:00am
8-K
yrsg2m v9cv
7 Aug 19
Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2019 Financial Results
8:08am
8-K
iyi91tr3tlzi2oqm2z
5 Aug 19
Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA
7:37am
8-K
c68zjz8d
24 Jul 19
Intra-Cellular Therapies Provides Update on FDA Advisory Committee Meeting for Lumateperone for the Treatment of Schizophrenia
6:07am
8-K
ej135u9nqd41bnduy6vq
8 Jul 19
Intra-Cellular Therapies Announces PositiveTop-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression
7:10am
CT ORDER
499i1d
5 Jul 19
Confidential treatment order
9:17am
8-K
8knd1v8ihupfdjn9
26 Jun 19
Submission of Matters to a Vote of Security Holders
4:31pm
DEFA14A
apve0faz7x wel6bb8fz
14 Jun 19
Additional proxy soliciting materials
4:31pm
8-K
ulocup
8 May 19
Intra-cellular Therapies Reports First Quarter 2019 Financial Results and Provides Corporate Update
7:35am
DEFA14A
e1wrm8c6ex49
30 Apr 19
Additional proxy soliciting materials
4:19pm
8-K
2xlbezmc7hggpl0zg6mr
27 Feb 19
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2018 Financial Results and Provides Corporate Update
7:43am